First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
value - McKesson trades at 0.3x sales and mid-teens P/E despite consistent FCF generation, attracting value investors seeking stable…
Rising rates have modest negative impact through higher working capital financing costs (company carries $50-60B in inventory)…
Watch on earnings: US prescription drug volume growth (IMS Health data, typically 2-4% annually driven by demographics), Specialty pharmaceutical revenue and gross profit contribution (target 25-30% of total gross profit), Generic drug inflation/deflation trends (CPI for prescription drugs, impacts inventory gains/losses).
One Sentence Summary:
McKesson: the story is balanced — us prescription drug volume trends (driven by aging demographics, glp-1 adoption, biosimilar launches).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.